Ragusa v. Louisiana Insurance Guaranty Association

District Court, E.D. Louisiana·Decided March 30, 2023·No. 2:21-cv-01971·Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

FRANK P. RAGUSA, JR. CIVIL ACTION VERSUS NO. 21-1971 LOUISIANA GUARANTY INSURANCE ASSOCIATION, ET AL. SECTION: “J”(5) ORDER AND REASONS Before the Court is a Daubert Motion to Exclude the Testimony of Dr. Stephen Terry Kraus and Dr. Rodney Landreneau (Rec. Doc. 371) filed by The Dow Chemical Company, Exxon Mobil Corporation, ExxonMobil Oil Corporation, Murphy Oil USA, Inc., Legacy Vulcan, LLC, CF Industries Nitrogen, LLC, Syngenta Crop Protection, LLC, Marathon Petroleum Company LP, Pharmacia LLC f/k/a Pharmacia Corporation f/k/a Monsanto Company, Riley Power, Inc., Rubicon LLC, Union Carbide Corporation, Bayer Cropscience, Inc., and Hexion Inc (“Defendants”). Plaintiff Frank P. Ragusa, Jr. opposes the motion; (Rec. Doc. 477); to which Murphy Oil and Exxon replied; (Rec. Doc. 561, 569). Considering the motion and legal memoranda, as well as the record and applicable law, the Court finds that the motion to exclude (Rec. Doc. 371) should be DENIED. FACTS AND PROCEDURAL BACKGROUND The facts of this case have been laid out in greater detail in previously issued Orders and Reasons. On July 16, 2021, Frank P. Ragusa, Jr. filed suit in Civil District Court for the Parish of Orleans, asserting Louisiana negligence and intentional tort claims for asbestos exposure against numerous defendants. Huntington Ingalls, Inc. (“Avondale”) removed the case to this Court on October 26, 2021. PARTIES’ ARGUMENTS

Defendants seek to exclude the testimony of Plaintiff’s radiation oncology expert Dr. Stephen Terry Kraus and thoracic surgery expert Dr. Rodney Landreneau. Defendants argue that, given the inadmissibility of the “no safe level of exposure” or “every exposure” theory, Dr. Kraus and Dr. Landreneau should be precluded from testifying at trial regarding any asbestos exposure from any particular product or at a particular jobsite. Defendants point to Dr. Kraus’s deposition testimony as proof

that he will rely on the “every exposure above background theory,” specifically his answers to questions regarding whether there is a threshold level of exposure required to be a significant contributing factor for developing mesothelioma. Defendants also emphasize Dr. Landreneau’s deposition testimony, including his answers to questions regarding his belief that any exposures below background will not cause mesothelioma. Defendants also argue that the doctors’ expert reports do not rely on a quantitative or qualitative assessment and instead simply assume that

each and every exposure to asbestos is above background and thus is a cause of Plaintiff’s mesothelioma, so the doctors’ specific causation opinions should be excluded. Plaintiff responds by arguing that the doctors do not rely upon an above background theory, nor is it even their opinion that all of Plaintiff’s exposures were significant. Plaintiffs note that Dr. Kraus specifically responded what the background level of asbestos is provided by literature and the EPA, and he also testified that a substantial contributing factor is “a question of more than” anything above background. Dr. Kraus explained that he considers Plaintiff’s exposure history to

specific products and worksites as well as scientific literature discussing exposure concentrations to which Plaintiff was exposed. He testified that with the removal of asbestos-containing Garlock gaskets, literature shows exposure concentrations from 0.69 f/cc up to 144.2 f/cc, which is orders of magnitude above the OSHA and NIOSH permissible exposure limits, as well as above the background concentrations. He provided similar analysis for friction exposures from the brakes in Plaintiff’s crane.

Plaintiff argues that his opinion that these exposures are significant is not based on the fact that they are merely above background as Defendants suggest but are based on the fact that they are well above occupational health standards and above exposures that have been shown in the literature to cause disease. As to Dr. Landreneau, Plaintiff argues that he also reviewed Plaintiff’s exposures and the literature’s descriptions of those exposures, and found it that Plaintiff’s exposures exceeded the levels known to cause disease. Plaintiff argues

that, although both doctors are aware of and referenced literature showing that short exposure durations and low exposure levels cause disease, Drs. Kraus and Landrenau did not reach their opinion that Plaintiff’s exposures were significant just because they were above background. DISCUSSION Defendants move to exclude Dr. Kraus and Dr. Landrenau from testifying regarding the specific causation of Plaintiff’s mesothelioma from specific products and

worksites on the basis of reliability. A qualified expert witness may testify if “(a) the expert's scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case.” Fed. R. Evid. 702. The United States Supreme Court’s decision in

Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), provides the analytical framework for determining whether expert testimony is admissible under Rule 702. The reliability of expert testimony “is determined by assessing whether the reasoning or methodology underlying the testimony is scientifically valid.” Knight v. Kirby Inland Marine Inc., 482 F.3d 347, 352 (5th Cir. 2007). A number of nonexclusive factors may be relevant to the reliability analysis, including: (1) whether the

technique at issue has been tested; (2) whether the technique has been subjected to peer review and publication; (3) the potential error rate; (4) the existence and maintenance of standards controlling the technique's operation; and (5) whether the technique is generally accepted in the relevant scientific community. Burleson v. Tex. Dep't of Criminal Justice, 393 F.3d 577, 584 (5th Cir. 2004). The reliability inquiry must remain flexible, however, as “not every Daubert factor will be applicable in every situation; and a court has discretion to consider other factors it deems relevant.” Guy v. Crown Equip. Corp., 394 F.3d 320, 325 (5th Cir. 2004); see also Runnels v. Tex. Children's Hosp. Select Plan, 167 F. App'x 377, 381 (5th Cir. 2006) (“[A] trial judge

has considerable leeway in determining how to test an expert’s reliability.”). Under Louisiana law, a plaintiff claiming asbestos-related injury must prove “significant exposure to the product complained of to the extent that it was a substantial factor in bringing about his injury.” Rando v. Anco Insulations Inc., 16 So. 3d 1065, 1091 (La. 2009). The plaintiff must show general causation—that a substance is capable of causing a particular injury or condition in the general

population—and specific causation—that a substance caused a particular individual's injury. Knight v. Kirby Inland Marine Inc., 482 F.3d 347, 351 (5th Cir. 2007).

Free access — add to your briefcase to read the full text and ask questions with AI

Ragusa v. Louisiana Insurance Guaranty Association, (E.D. La. 2023).

Ragusa v. Louisiana Insurance Guaranty Association (Ragusa v. Louisiana Insurance Guaranty Association) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Burleson v. Texas Department of Criminal Justice
393 F.3d 577 (Fifth Circuit, 2004)
Guy v. Crown Equipment Corp.
394 F.3d 320 (Fifth Circuit, 2004)
Runnels v. Texas Children's Hospital Select Plan
167 F. App'x 377 (Fifth Circuit, 2006)
Knight v. Kirby Inland Marine Inc.
482 F.3d 347 (Fifth Circuit, 2007)
Rock v. Arkansas
483 U.S. 44 (Supreme Court, 1987)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
United States v. Wen Chyu Liu
716 F.3d 159 (Fifth Circuit, 2013)
Rando v. Anco Insulations Inc.
16 So. 3d 1065 (Supreme Court of Louisiana, 2009)
Williams v. Boeing
23 F.4th 507 (Fifth Circuit, 2022)
Vedros v. Northrop Grumman Shipbuilding, Inc.
119 F. Supp. 3d 556 (E.D. Louisiana, 2015)